Insmed Incorporated (NASDAQ:INSM) Insider Sells $220,403.04 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.

Insmed Stock Down 0.7 %

Shares of INSM traded down $0.47 during mid-day trading on Friday, reaching $65.25. The company’s stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a market cap of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. The business has a fifty day moving average of $71.29 and a 200 day moving average of $72.44.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.10) EPS. As a group, analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC acquired a new position in shares of Insmed in the third quarter worth $30,000. GAMMA Investing LLC increased its position in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares in the last quarter. JCIC Asset Management Inc. acquired a new stake in shares of Insmed during the 3rd quarter valued at about $133,000. Finally, Quantbot Technologies LP bought a new stake in shares of Insmed in the 3rd quarter valued at approximately $133,000.

Analysts Set New Price Targets

INSM has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. increased their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. Finally, Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.